arrow
C

Chenyu Lin

Duke University School of Medicine
H指数:15
被引数:867

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Choice of hypomethylating agent for newly diagnosed TP53-mutant acute myeloid Leukemia: a COMMAND registry study
Leukemia
IF13.4
2026-08-310
PRE
Hybrid-delivered cognitive behavioral symptom management and activity coaching intervention for patients following hematopoietic stem cell transplant or CAR T-cell therapy: Protocol of a randomized controlled trial

造血干细胞移植或CAR T细胞疗法后患者的混合递送认知行为症状管理及活动指导干预:一项随机对照试验方案

2026-07-010
OAAI
Improved Outcomes with TKI Maintenance Following Brexucabtagene Autoleucel in Philadelphia-chromosome ALL

在费城染色体阳性急性淋巴细胞白血病中使用Brexucabtagene Autoleucel治疗后,TKI维持疗法可改善疗效

2026-06-290
OA
Consensus Recommendations for CAR T Cell Administration in Adult Acute Lymphoblastic Leukemia: A Modified Delphi Study

成人急性淋巴细胞白血病CAR T细胞输注的共识建议:一项改良德尔菲研究

Blood
IF23.1
2026-05-220
PRE
Extended Versus Standard Hypomethylating Agent Dosing in Combination With Venetoclax in Patients With Newly Diagnosed Acute Myeloid Leukemia

延长与标准低甲基化药物剂量联合维奈克拉用于新诊断急性髓系白血病患者的比较

2026-05-160
OAAI
Musculoskeletal Adverse Events Following BCMA CAR-T Cell Therapy in Multiple Myeloma: Clinical Characteristics and Immune Correlates

BCMA CAR-T细胞疗法在多发性骨髓瘤中引起的肌肉骨骼不良事件:临床特征和免疫相关性

2026-02-180
PRE
Blinatumomab Non-response Correlates with Poor Survival After Brexucabtagene Autoleucel in B-cell ALL

Blinatumomab无应答与Brexucabtagene autoleucel治疗后B细胞急性淋巴细胞白血病患者预后不良相关

Blood
IF23.1
2026-02-090
PRE
Single-centre analysis of prophylactic dexamethasone on the incidence and severity of cytokine release syndrome and immune effector cell-associated neurotoxicity in patients receiving axicabtagene ciloleucel

预防性地塞米松对接受axicabtagene ciloleucel的患者细胞因子释放综合征和免疫效应细胞相关神经毒性的发生率和严重程度的单中心分析

2026-01-190
PRE
Spectrum, prevalence, and clinical correlates of PPM1D mutations in patients with clonal hematopoiesis and clonal cytopenias.

PPM1D基因突变的谱系、患病率及与克隆性造血和克隆性血细胞减少症患者的临床相关性。

2026-01-090
OAAI
CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemia

CAR HEMATOTOX 独立预测急性淋巴细胞白血病接受CD19 CAR-T疗法后的结局

2025-10-080
OAAI
The impact of social determinants of health on outcomes of brexucabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemia

社会决定因素对成人复发/难治性B细胞急性淋巴细胞白血病患者brexucabtagene autoleucel治疗结局的影响

2025-08-230
OAAI
Clinical and molecular characterization of TP53-mutant acute lymphoblastic leukemia in adults

成人TP53突变急性淋巴细胞白血病的临床与分子特征

2025-08-140
OAAI
Heterogeneity in outcomes of TP53-mutated myeloproliferative neoplasms based on disease phenotype and mutational status

TP53突变性骨髓增殖性肿瘤的结局异质性,基于疾病表型和突变状态

2025-05-220
PRE
Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the US Multiple Myeloma Immunotherapy Consortium

复发难治性多发性骨髓瘤(RRMM)老年患者接受teclistamab治疗后的结局:一项来自美国多发性骨髓瘤免疫治疗联盟的多中心研究

2025-05-090
OA
Photocrosslinked gelatin methacryloyl/hyaluronic acid methacryloyl composite hydrogels loaded with bone morphogenetic protein 2-black phosphorus nanosheets for bone regeneration

光交联明胶甲基丙烯酰/透明质酸甲基丙烯酰复合水凝胶负载骨形态发生蛋白2-黑色磷纳米片用于骨再生

2025-04-010
PRE
Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL
2024-12-102
OAAI